Modeling of Functional Assessment Questionnaire (FAQ) as continuous bounded data from the ADNI database

被引:22
作者
Ito, K. [1 ]
Hutmacher, M. M. [2 ]
Corrigan, B. W. [1 ]
机构
[1] Pfizer Inc, Primary Care Business Unit, Groton, CT 06340 USA
[2] Ann Arbor Pharmacometr Grp, Ann Arbor, MI 48104 USA
基金
加拿大健康研究院; 美国国家卫生研究院;
关键词
Bounded outcome data; Disease progression; Alzheimer's disease; ADNI; POPULATION PHARMACODYNAMIC MODEL; ALZHEIMERS-DISEASE; PROGRESSION; VALIDATION;
D O I
10.1007/s10928-012-9271-3
中图分类号
R9 [药学];
学科分类号
1007 ;
摘要
An assessment of abilities to function independently in daily life is an important clinical endpoint for all Alzheimer's disease (AD) patients and caregivers. A mathematical model was developed to describe the natural history of change of the Functional Assessment Questionnaire (FAQ) from data obtained in normal elderly, mild cognitive impairment, and mild AD in the AD neuroimaging initiative (ADNI) study. FAQ is a bounded outcome (ranging from 0 to 30), with 0 scored as "no impairment" and 30 as "severely impaired". Since many normal elderly patients had 0 scores and some AD patients had scores of 30 in the ADNI database, a censored approach for handling the boundary data was compared with a standard approach, which ignores the bounded nature of the data. Baseline severity, ApoE4 genotype, age, sex, and imaging biomarkers were tested as covariates. The censored approach greatly improved the predictability of the disease progression in FAQ scores. The basic method for handling boundary data used in this analysis is also applicable to handle boundary observations for numerous other endpoints.
引用
收藏
页码:601 / 618
页数:18
相关论文
共 27 条
  • [11] RESULTS AND VALIDATION OF A POPULATION PHARMACODYNAMIC MODEL FOR COGNITIVE EFFECTS IN ALZHEIMER PATIENTS TREATED WITH TACRINE
    HOLFORD, NHG
    PEACE, KE
    [J]. PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA, 1992, 89 (23) : 11471 - 11475
  • [12] METHODOLOGIC ASPECTS OF A POPULATION PHARMACODYNAMIC MODEL FOR COGNITIVE EFFECTS IN ALZHEIMER PATIENTS TREATED WITH TACRINE
    HOLFORD, NHG
    PEACE, KE
    [J]. PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA, 1992, 89 (23) : 11466 - 11470
  • [13] Estimating transformations for repeated measures modeling of continuous bounded outcome data
    Hutmacher, Matthew M.
    French, Jonathan L.
    Krishnaswami, Sriram
    Menon, Sujatha
    [J]. STATISTICS IN MEDICINE, 2011, 30 (09) : 935 - 949
  • [14] Disease progression model for cognitive deterioration from Alzheimer's Disease Neuroimaging Initiative database
    Ito, Kaori
    Corrigan, Brian
    Zhao, Qinying
    French, Jonathan
    Miller, Raymond
    Soares, Holly
    Katz, Elyse
    Nicholas, Timothy
    Billing, Bill
    Anziano, Richard
    Fullerton, Terence
    [J]. ALZHEIMERS & DEMENTIA, 2011, 7 (02) : 151 - 160
  • [15] Disease progression meta-analysis model in Alzheimer's disease
    Ito, Kaori
    Ahadieh, Sima
    Corrigan, Brian
    French, Jonathan
    Fullerton, Terence
    Tensfeldt, Thomas
    [J]. ALZHEIMERS & DEMENTIA, 2010, 6 (01) : 39 - 53
  • [16] Pathogenic Protein Seeding in Alzheimer Disease and Other Neurodegenerative Disorders
    Jucker, Mathias
    Walker, Lary C.
    [J]. ANNALS OF NEUROLOGY, 2011, 70 (04) : 532 - 540
  • [17] A 3-STEP APPROACH COMBINING BAYESIAN REGRESSION AND NONMEM POPULATION ANALYSIS - APPLICATION TO MIDAZOLAM
    MAITRE, PO
    BUHRER, M
    THOMSON, D
    STANSKI, DR
    [J]. JOURNAL OF PHARMACOKINETICS AND BIOPHARMACEUTICS, 1991, 19 (04): : 377 - 384
  • [18] BUILDING POPULATION PHARMACOKINETIC PHARMACODYNAMIC MODELS .1. MODELS FOR COVARIATE EFFECTS
    MANDEMA, JW
    VEROTTA, D
    SHEINER, LB
    [J]. JOURNAL OF PHARMACOKINETICS AND BIOPHARMACEUTICS, 1992, 20 (05): : 511 - 528
  • [19] Mould D.R., 2006, Pharmacometrics, P547, DOI DOI 10.1002/9780470087978.CH21
  • [20] Common variants at MS4A4/MS4A6E, CD2AP, CD33 and EPHA1 are associated with late-onset Alzheimer's disease
    Naj, Adam C.
    Jun, Gyungah
    Beecham, Gary W.
    Wang, Li-San
    Vardarajan, Badri Narayan
    Buros, Jacqueline
    Gallins, Paul J.
    Buxbaum, Joseph D.
    Jarvik, Gail P.
    Crane, Paul K.
    Larson, Eric B.
    Bird, Thomas D.
    Boeve, Bradley F.
    Graff-Radford, Neill R.
    De Jager, Philip L.
    Evans, Denis
    Schneider, Julie A.
    Carrasquillo, Minerva M.
    Ertekin-Taner, Nilufer
    Younkin, Steven G.
    Cruchaga, Carlos
    Kauwe, John S. K.
    Nowotny, Petra
    Kramer, Patricia
    Hardy, John
    Huentelman, Matthew J.
    Myers, Amanda J.
    Barmada, Michael M.
    Demirci, F. Yesim
    Baldwin, Clinton T.
    Green, Robert C.
    Rogaeva, Ekaterina
    St George-Hyslop, Peter
    Arnold, Steven E.
    Barber, Robert
    Beach, Thomas
    Bigio, Eileen H.
    Bowen, James D.
    Boxer, Adam
    Burke, James R.
    Cairns, Nigel J.
    Carlson, Chris S.
    Carney, Regina M.
    Carroll, Steven L.
    Chui, Helena C.
    Clark, David G.
    Corneveaux, Jason
    Cotman, Carl W.
    Cummings, Jeffrey L.
    DeCarli, Charles
    [J]. NATURE GENETICS, 2011, 43 (05) : 436 - +